Long-term impact of peritoneal dialysis ultrafiltration on cardiorenal patients.

IF 2.4 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Sara Núñez-Delgado, Maria Antonieta Azancot, Ana Belén Méndez Fernandez, Juan León-Román, Natalia Ramos Terrades, Néstor Toapanta, Ana Sánchez-Escuredo, Jordi Comas, María José Soler
{"title":"Long-term impact of peritoneal dialysis ultrafiltration on cardiorenal patients.","authors":"Sara Núñez-Delgado, Maria Antonieta Azancot, Ana Belén Méndez Fernandez, Juan León-Román, Natalia Ramos Terrades, Néstor Toapanta, Ana Sánchez-Escuredo, Jordi Comas, María José Soler","doi":"10.1159/000546924","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) prevalence is increasing, and its prognosis worsens in the presence of other comorbidities. Up to 70% of patients develop cardio-renal syndrome (CRS), which is associated with diuretic resistance or kidney deterioration over time. Peritoneal dialysis (PD) for ultrafiltration (PD-UF) could be a potential therapeutic option in CRS, although its long-term outcomes have not been described.</p><p><strong>Methods: </strong>Retrospective registry study of the Catalan Renal Registry on patients with PD-UF indication between 2013-2022. Baseline clinical characteristics and follow-up until December/2022 was studied.</p><p><strong>Results: </strong>Of the 1874 incident patients on PD,198(10.6%) were PD-UF,73.2% of the patients were male and the mean age was70.7±9.3 years. Median eGFR at start was 22.6 [IQR14.8-32.8] ml/min·1.73m2 and 75.0% have an eGFR above 15 ml/min·1.73m2. Previous history of ischemic heart disease, arrhythmia or cardiac surgery was recorded, 57.6% of patients had ≥2 of these pathologies. The most common HF etiology was ischemic heart disease in 21.7% of patients. Median overall patient survival was 21 months [IQR17.3-24.3]. Technique survival at one year was 94.8%, and 27 patients were transferred to other renal replacement therapy (hemodialysis or kidney transplantation). In the cox multivariate analysis, age>75 years (HR 1.76[95%CI 1.20-2.59]), mild frailty (HR2.18[95%CI 1.17-2.59]), severe frailty (HR 17.62[95%CI 1.20-55.48]) and the burden of cardiac disease (2 categories HR 2.17[95%CI 1.05-4.47]; 3 categories HR 2.26 [95%CI 1.05-4.89]) were associated with poor overall survival. Technique survival was associated with eGFR (<30 ml/min·1.73m2 HR 5.64[95%CI 1.32-24.18]) and body mass index (<20 kg/m2 HR 6.53 [95%CI 1.06-40.12]) at baseline.</p><p><strong>Conclusion: </strong>PD-HF is a feasible option in patients with advanced HF and CRS. The complexity of this population increases with older age, frailty and higher cardiac burden.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"1-25"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiorenal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546924","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Heart failure (HF) prevalence is increasing, and its prognosis worsens in the presence of other comorbidities. Up to 70% of patients develop cardio-renal syndrome (CRS), which is associated with diuretic resistance or kidney deterioration over time. Peritoneal dialysis (PD) for ultrafiltration (PD-UF) could be a potential therapeutic option in CRS, although its long-term outcomes have not been described.

Methods: Retrospective registry study of the Catalan Renal Registry on patients with PD-UF indication between 2013-2022. Baseline clinical characteristics and follow-up until December/2022 was studied.

Results: Of the 1874 incident patients on PD,198(10.6%) were PD-UF,73.2% of the patients were male and the mean age was70.7±9.3 years. Median eGFR at start was 22.6 [IQR14.8-32.8] ml/min·1.73m2 and 75.0% have an eGFR above 15 ml/min·1.73m2. Previous history of ischemic heart disease, arrhythmia or cardiac surgery was recorded, 57.6% of patients had ≥2 of these pathologies. The most common HF etiology was ischemic heart disease in 21.7% of patients. Median overall patient survival was 21 months [IQR17.3-24.3]. Technique survival at one year was 94.8%, and 27 patients were transferred to other renal replacement therapy (hemodialysis or kidney transplantation). In the cox multivariate analysis, age>75 years (HR 1.76[95%CI 1.20-2.59]), mild frailty (HR2.18[95%CI 1.17-2.59]), severe frailty (HR 17.62[95%CI 1.20-55.48]) and the burden of cardiac disease (2 categories HR 2.17[95%CI 1.05-4.47]; 3 categories HR 2.26 [95%CI 1.05-4.89]) were associated with poor overall survival. Technique survival was associated with eGFR (<30 ml/min·1.73m2 HR 5.64[95%CI 1.32-24.18]) and body mass index (<20 kg/m2 HR 6.53 [95%CI 1.06-40.12]) at baseline.

Conclusion: PD-HF is a feasible option in patients with advanced HF and CRS. The complexity of this population increases with older age, frailty and higher cardiac burden.

腹膜透析超滤对心肾患者的长期影响。
背景:心力衰竭(HF)的患病率正在增加,并且在存在其他合并症时其预后恶化。高达70%的患者会出现心肾综合征(CRS),这与利尿剂抵抗或肾脏恶化有关。腹膜透析(PD)治疗超滤(PD- uf)可能是CRS的一种潜在治疗选择,尽管其长期结果尚未描述。方法:对2013-2022年间PD-UF指征患者的加泰罗尼亚肾脏登记处进行回顾性登记研究。研究基线临床特征和随访至2022年12月。结果:1874例PD患者中,PD- uf 198例(10.6%),男性占73.2%,平均年龄70.7±9.3岁。开始时的中位eGFR为22.6 [IQR14.8-32.8] ml/min·1.73m2, 75.0%的患者eGFR高于15 ml/min·1.73m2。既往有缺血性心脏病、心律失常或心脏手术史,其中57.6%的患者有以上2项以上病史。最常见的HF病因是缺血性心脏病,占21.7%。患者中位总生存期为21个月[IQR17.3-24.3]。1年技术生存率为94.8%,27例患者转移到其他肾脏替代治疗(血液透析或肾移植)。在cox多因素分析中,年龄为50 ~ 75岁(HR 1.76[95%CI 1.20 ~ 2.59])、轻度虚弱(HR2.18[95%CI 1.17 ~ 2.59])、重度虚弱(HR 17.62[95%CI 1.20 ~ 55.48])和心脏疾病负担(HR 2.17[95%CI 1.05 ~ 4.47]);3个类别(HR 2.26 [95%CI 1.05-4.89])与总生存率较差相关。技术生存率与eGFR相关(结论:PD-HF是晚期HF和CRS患者的可行选择)。这一人群的复杂性随着年龄增大、身体虚弱和心脏负担加重而增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiorenal Medicine
Cardiorenal Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-UROLOGY & NEPHROLOGY
CiteScore
5.40
自引率
2.60%
发文量
25
审稿时长
>12 weeks
期刊介绍: The journal ''Cardiorenal Medicine'' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信